Search review questions

1a.'Clinical apnea' after initiation of treatment – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation

1b. 'Clinical apnea' after initiation of treatment – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation

2a. Failed apnea reduction after 2–7 days – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation

3a. Chronic lung disease at 36 weeks' postmenstrual age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation

3b. Chronic lung disease at 36 weeks' postmenstrual age – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation

3c. Chronic lung disease at 36 weeks' postmenstrual age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation

4a. Death (at any time during initial hospitalization) – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation

4b. Death (at any time during initial hospitalization) – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation

5a.Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation

5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation

5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation

6a. Side effects causing cessation of therapy – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation

6b. Side effects causing cessation of therapy – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation

2c. Need for positive pressure ventilation after initiation of treatment – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea

3a. Chronic lung disease at 36 weeks' postmenstrual age (defined as supplemental oxygen at 36 weeks' gestation) – doxapram compared to no treatment for the treatment of apnea · treatment of apnea

3b. Chronic lung disease at 36 weeks' postmenstrual age (defined as supplemental oxygen at 36 weeks' gestation) – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea

3c. Chronic lung disease at 36 weeks' postmenstrual age (defined as supplemental oxygen at 36 weeks' gestation) – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea

Pain · postoperative pain in preterm and term infants

Major neurodevelopmental disability in children aged three to five years · postoperative pain in preterm and term infants

Cognitive and educational outcomes in children more than five years old · postoperative pain in preterm and term infants

Severe retinopathy of prematurity (defined as stage 3 or greater) · postoperative pain in preterm and term infants

Severe intraventricular hemorrhage (grade 3 or greater) on cranial ultrasound, as per Papile classification · postoperative pain in preterm and term infants

Major neurodevelopmental disability in children aged 18 to 24 months · postoperative pain in preterm and term infants

Major neurodevelopmental disability in children aged three to five years · postoperative pain in preterm and term infants

Cognitive and educational outcomes in children more than five years old · postoperative pain in preterm and term infants

All‐cause mortality during initial hospitalization · postoperative pain in preterm and term infants

Major neurodevelopmental disability in children aged 18 to 24 months · postoperative pain in preterm and term infants

Severe retinopathy of prematurity (defined as stage 3 or greater) · postoperative pain in preterm and term infants

Severe intraventricular hemorrhage (grade 3 or greater) on cranial ultrasound, as per Papile classification · postoperative pain in preterm and term infants

Major neurodevelopmental disability in children aged three to five years · postoperative pain in preterm and term infants

Cognitive and educational outcomes in children more than five years old · postoperative pain in preterm and term infants

Severe retinopathy of prematurity (defined as stage 3 or greater) · postoperative pain in preterm and term infants

Severe intraventricular hemorrhage (grade 3 or greater) on cranial ultrasound, as per Papile classification · postoperative pain in preterm and term infants

Pain · postoperative pain in preterm and term infants

Major neurodevelopmental disability in children aged 18 to 24 months · postoperative pain in preterm and term infants

Mortality or neurodevelopment disability at 18 to 24 months' corrected age ‐ not reported · clinically diagnosed neonatal seizures

Proportion of infants who achieve seizure control after the first loading dose of ASM ‐ not reported · neonates with EEG‐confirmed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with EEG‐confirmed seizures

Proportion of infants who achieve seizure control after maximal loading dose ‐ not reported · neonates with clinically diagnosed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with clinically diagnosed seizures

Proportion of infants who achieve seizure control after the maximal loading dose of ASM ‐ not reported · Neonates with clinically diagnosed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · Neonates with clinically diagnosed seizures

Mortality or neurodevelopment disability at 18 to 24 months' corrected age ‐ not reported · neonates with EEG‐confirmed seizures

Proportion of infants who achieve seizure control after the maximal loading dose of ASM ‐ not reported · neonates with clinically diagnosed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with clinically diagnosed seizures

Proportion of infants who achieve seizure control after the maximal loading dose of the ASM ‐ not reported · neonates with EEG‐confirmed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with EEG‐confirmed seizures

Proportion of infants who achieve seizure control after first loading dose of ASM ‐ not reported · neonates with EEG‐confirmed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates with clinically diagnosed seizures

Mortality or neurodevelopmental disability at 18 to 24 months' corrected age ‐ not reported · neonates